Article

Patients prefer custom over conventional LASIK ablation

Milan, Italy-A comparison of custom and conventional LASIK ablations showed that both procedures provided very good results in terms of the uncorrected and best-corrected visual acuities (UCVA, BCVA) and refractive outcomes. Patients expressed greater quality of vision, however, with the results of the custom treatment, likely because of the better higher-order aberration values in that group, reported Luca Vigo, MD.

"The choice between custom or conventional ablation is still controversial. Some surgeons claim that custom ablation is superior to conventional ablation, and other surgeons claim that there is no need to perform a custom ablation except in particular cases that need iris registration or that are highly aberrated," said Dr. Vigo, associate ophthalmologist, Carones Ophthalmology Center, Milan, Italy.

The mean BCVA was 1.35 ± 0.20 in the custom group and 1.38 + 0.20 in the conventional group. Most of the patients gained lines postoperatively; one patient in the custom group lost a line of BCVA 3 months postoperatively.

Spherical aberrations

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
© 2025 MJH Life Sciences

All rights reserved.